Contrast Agents Market Scope
Contrast materials, also known as contrast agents or contrast media, are used to improve x-ray, computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound images of the inside of the body. Contrast materials are frequently used to help the radiologist distinguish between normal and pathological situations. Contrast materials are not dyes that stain internal organs permanently. They are compounds that alter the way x-rays and other imaging instruments interact with the body for a short period of time. Contrast materials, when injected into the body before an imaging exam, cause particular structures or tissues in the body to appear differently on the images than they would if no contrast material had been injected. Contrast materials help distinguish or contrast selected areas of the body from surrounding tissue. By improving the visibility of specific organs, blood vessels or tissues, contrast materials help physicians diagnose medical conditions.
The Contrast Agents market study is segmented by Type (Iodine-based, Barium-Sulfate and Gadolinium), by Application (Interventional Radiology and Interventional Cardiology) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansion and acquisition to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Asia Pacific Players will contribute to the maximum growth of Global Contrast Agents market throughout the predicted period.
E Healthcare (United States), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging, Inc. (United States), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals Ltd. (India), SANOCHEMIA Pharmazeutika GmbH (Austria), Taejoon Pharm (South Korea), Jodas Expoim (India), Nano Therapeutics Pvt. Ltd. (India), Kiran X-ray (India), iMax Diagnostic Imaging Limited (Ireland) and K DIAM EXIM (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Congruent Pharmachem Private Limited (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China) and Subhra Pharma Pvt. Ltd. (India).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Contrast Agents market by Type, Application and Region.
On the basis of geography, the market of Contrast Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In 2020, GE Healthcare Pharma Limited acquired the ownership of Daiichi Sankyo’s four diagnostic agents in Japan.
In Feb. 22, 2021 - Bracco Announces U.S. FDA Approval of 20-Vial Configuration of LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use. LUMASON is an ultrasound contrast agent indicated for use: in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms, in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients, and in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients and In 2020, Bracco Imaging SpA received approval from the US FDA for its product ProHance, which is an MRI contrast agent for use in neonates and pediatric patients under two years of age.
- Increasing Volume of CT and MRI Examinations Performed
- Increasing Prevalence of Chronic Diseases
- Rising Approvals of Contrast Agents
- Increasing Research on Contrast Agents
- Rising Number of Diagnostic Centers and Hospitals
- Side-effects and Allergic Reactions Associated with Contrast Agents
- Technological Advancements in Imaging Solutions
- Restriction and Withdrawal of Linear Gadolinium-based Contrast Agents
Key Target AudienceManufacturers of Contrast Agent, Suppliers of Contrast Agent, Wholesalers, Distributors and Retailers of Contrast Agent, Healthcare Industry, Regulatory Bodies and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Contrast Agents Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.